TRIAL DETAIL

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors

Drug:
Trial Name:
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors
NCT#:
Conditions:
Solid Tumors
Status:
Terminated
Phase:
1
Start Date 03/01/2014
Age of Trial (yrs) 8.3
Treatment Phase:
Gleevec-resistant
Drug Category:
MEK Inhibitor + CDK4/6 Inhibitor
Strategy:
Block related tumor signal paths
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
200344
Sponsor:
GlaxoSmithKline
Patient Contact:
US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:
Other Inclusion criteria for Part 1
Histologically or cytologically confirmed diagnosis of solid tumor malignancy that is not responsive to standard therapies or for which there is no approved or curative therapy.

Exclusion Criteria:

Prior treatment with a MEK inhibitor or a CDK4/6 inhibitor.
BRAFV600 mutation positive.

Trial Links

Trial Results

Drug Information

Trial Sites

Name
Address
City
State
Zip
Country
1505 Holcombe Blvd.
Houston
TX
77030
USA
55 Fruit Street
Boston
MA
02114
USA
2220 Pierce Ave.
Nashville
TN
37232
USA